Cetera Advisors LLC Biomarin Pharmaceutical Inc Transaction History

Cetera Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$83.81 - $99.0 $362,394 - $428,076	4,324 Added 175.7%	6,785 $592,000
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $187,577 - $242,433	2,461 New	2,461 $237,000
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $1.15 Million - $1.54 Million	-13,131 Reduced 84.17%	2,469 $240,000
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $337,154 - $452,552	4,166 Added 36.44%	15,600 $1.61 Million
Q3 2022 Nov 10, 2022	BUY	$82.16 - $96.94 $384,673 - $453,873	4,682 Added 69.34%	11,434 $969,000
Q2 2022 Aug 11, 2022	BUY	$71.48 - $86.85 $482,632 - $586,411	6,752 New	6,752 $560,000

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisors LLC with notifications on news.